Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601094 | 0.87 | ESR2 (0.53) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL3600122 | 0.86 | ESR2 (0.52) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL13037519 | 0.86 | ESR2 (0.55) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL3597423 | 0.83 | ESR2 (0.49) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL29405503 | 0.82 | ESR2 (0.55) | ESR2NR1H2MAPTMAPK1ABHD6 | |
| SCHEMBL19642882 | 0.82 | ESR2 (0.55) | ESR2NR1H2MAPTMAPK1ABHD6 | |
| SCHEMBL7893732 | 0.81 | ESR1 (0.48) | ESR2ABHD6 | |
| SCHEMBL38653305 | 0.80 | MAPT (0.49) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL4880504 | 0.80 | ESR2 (0.53) | ESR2NR1H2MAPTALDH1A1LMNA | |
| SCHEMBL2119725 | 0.79 | ABHD6 (0.65) | ESR2NR1H2MAPTMAPK1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | ESR2 1497/4885NR1H2 176/4885MAPT 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.